FATE
Price
$0.93
Change
-$0.08 (-7.92%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
115.74M
50 days until earnings call
KALV
Price
$12.00
Change
+$0.08 (+0.67%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
589.06M
One day until earnings call
Ad is loading...

FATE vs KALV

Header iconFATE vs KALV Comparison
Open Charts FATE vs KALVBanner chart's image
Fate Therapeutics
Price$0.93
Change-$0.08 (-7.92%)
Volume$63K
Capitalization115.74M
KalVista Pharmaceuticals
Price$12.00
Change+$0.08 (+0.67%)
Volume$13.87K
Capitalization589.06M
FATE vs KALV Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. KALV commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and KALV is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (FATE: $1.01 vs. KALV: $11.92)
Brand notoriety: FATE and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 75% vs. KALV: 143%
Market capitalization -- FATE: $115.74M vs. KALV: $589.06M
FATE [@Biotechnology] is valued at $115.74M. KALV’s [@Biotechnology] market capitalization is $589.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while KALV’s TA Score has 2 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 5 bearish.
  • KALV’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than KALV.

Price Growth

FATE (@Biotechnology) experienced а -9.82% price change this week, while KALV (@Biotechnology) price change was +4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

FATE is expected to report earnings on Apr 30, 2025.

KALV is expected to report earnings on Jul 03, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($589M) has a higher market cap than FATE($116M). KALV YTD gains are higher at: 40.732 vs. FATE (-38.788). KALV has higher annual earnings (EBITDA): -162.3M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. KALV (136M). KALV has less debt than FATE: KALV (6.21M) vs FATE (99M). FATE has higher revenues than KALV: FATE (13.4M) vs KALV (0).
FATEKALVFATE / KALV
Capitalization116M589M20%
EBITDA-177.57M-162.3M109%
Gain YTD-38.78840.732-95%
P/E RatioN/AN/A-
Revenue13.4M0-
Total Cash297M136M218%
Total Debt99M6.21M1,594%
FUNDAMENTALS RATINGS
FATE vs KALV: Fundamental Ratings
FATE
KALV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
9742
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is somewhat better than the same rating for KALV (60) in the Pharmaceuticals Other industry. This means that FATE’s stock grew somewhat faster than KALV’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that FATE’s stock grew similarly to KALV’s over the last 12 months.

FATE's SMR Rating (94) in the Biotechnology industry is in the same range as KALV (97) in the Pharmaceuticals Other industry. This means that FATE’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for FATE (97) in the Biotechnology industry. This means that KALV’s stock grew somewhat faster than FATE’s over the last 12 months.

KALV's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as FATE (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEKALV
RSI
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 20 days ago
85%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 18 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALBCX75.690.72
+0.96%
Alger Growth & Income C
KCIIX13.410.10
+0.75%
Knights of Columbus International Eq I
PSPJX27.420.16
+0.59%
Principal Large Cap S&P 500 Index J
FGJMX111.43-0.16
-0.14%
Fidelity Advisor Communication ServicesI
HDCTX9.63-0.02
-0.21%
Rational Equity Armor Fund Instl

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.88%
ALLO - FATE
57%
Loosely correlated
+7.92%
NTLA - FATE
55%
Loosely correlated
+4.55%
NKTX - FATE
53%
Loosely correlated
-2.65%
RCKT - FATE
52%
Loosely correlated
-2.45%
CRSP - FATE
52%
Loosely correlated
+5.13%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with IDYA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-0.50%
IDYA - KALV
43%
Loosely correlated
-3.20%
ATXS - KALV
42%
Loosely correlated
-3.58%
AVIR - KALV
42%
Loosely correlated
-0.33%
FATE - KALV
41%
Loosely correlated
-2.88%
TRDA - KALV
40%
Loosely correlated
+3.36%
More